Xylem (XYL) stock is back in focus after the company appointed Andrea van der Berg as Executive Vice President and Chief Financial Officer, effective September 1, 2026, succeeding William Grogan.

Xylem's latest leadership changes come after a mixed share price pattern, with the stock down 7.5% on a 7 day share price return and 16.9% year to date, yet supported by a 3 year total shareholder return of 18.79%. This contrasts with a weaker 1 year total shareholder return and suggests that momentum has recently faded even as long term holders still see a net gain.

If this CFO transition has you thinking about where else capital could work, it might be a good moment to review power grid and infrastructure peers via the 39 power grid technology and infrastructure stocks.

Recent weakness in Xylem shares sits next to ongoing profitability and leadership changes. Is this pullback telling you something new about the business, or is sentiment resetting and creating a different entry point on valuation?

Most Popular Narrative: 24.4% Undervalued

The most followed valuation narrative for Xylem points to a fair value of $150.65 per share compared with the latest close at $113.94. That gap rests on specific assumptions about long term contracts, digital water solutions and margin improvement that investors will want to understand.

Successful post-acquisition integration of Evoqua and revenue synergies from services expansion are accelerating Xylem's shift toward more recurring, higher-margin aftermarket and services revenue streams, boosting earnings stability and long-term profitability.

Read the complete narrative. Read the complete narrative.

Want to see what is baked into that $150.65 figure? The narrative leans on steady revenue growth, meaningfully higher margins and a premium future earnings multiple. Curious how those pieces fit together into one long term return profile.

Result: Fair Value of $150.65 (UNDERVALUED)

However, Xylem's story also depends on government infrastructure funding arriving as expected and on smooth execution of large acquisitions like Evoqua. Both factors carry a clear risk of setbacks.

Next Steps

If the mix of caution and optimism around Xylem has you thinking, now is a good time to look at the details yourself and move quickly to shape your own view using the 6 key rewards.

Looking for more investment ideas beyond Xylem?

If you are reassessing Xylem and want fresh angles for your next move, now is the moment to scan other opportunities before the market prices them differently.

• Target potential hidden value by reviewing companies that screen as high quality and currently priced as 50 high quality undervalued stocks.
• Strengthen your focus on balance sheet resilience by checking out stocks highlighted in the solid balance sheet and fundamentals stocks screener (50 results).
• Spot opportunities that others may be overlooking by scanning the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.